Key points from article :
CARMAT secures €7 million in funding to extend its cash runway into early 2024
The company anticipates a rise in European sales, projecting €4-6 million in revenue for the latter half of 2023
CARMAT's Aeson artificial heart implants have reached a steady pace of one per week
The company aims to expand production capacity to 500 artificial hearts annually by the end of 2023
CARMAT is actively exploring additional financing options to meet its operational and investment needs through 2024
